The FDA strengthens its guidance for pain reliever use in pregnant women; the United States sees its greatest increase in coronavirus disease 2019 (COVID-19) cases since August; studies point to association of blood type and COVID-19 risk.
The FDA announced in a Drug Safety Communication that it is requiring label changes for common nonsteroidal anti-inflammatory drugs such as Advil and Aleve, the Associated Press reports. According to the announcement, pregnant women should avoid this class of drugs during the last 4 months of pregnancy. Previous warnings cautioned against use during the last 3 months of pregnancy. The FDA said the drugs can cause a rare but serious complication that may harm the fetus and can lead to kidney problems in the fetus, which can result in low levels of amniotic fluid in the womb. However, the warning does not apply to low-dose aspirin when recommended by a doctor.
The United States reported 60,000 new coronavirus disease 2019 (COVID-19) infections for the first time since early August on Thursday, according to The Washington Post. Over 36,000 individuals are currently hospitalized with the disease, and data show the crisis is not localized to certain regions. Rising cases are being reported almost everywhere in the country, with 44 states now reporting higher caseloads than in mid-September. In particular, more rural states like Wisconsin and Illinois have both reported newly reported caseloads greater than during the states’ first waves in April and May. Ohio, Indiana, New Mexico, North Dakota, Montana, and Colorado also have reported new highs.
Two studies published in the journal Blood Advance suggest blood type may play a role in the risk of becoming infected with COVID-19 or developing life-threatening complications from the illness, NBC News reports. However, the results do not mean that any single blood type is more protective or more dangerous when it comes to the virus. The results also will not change how doctors treat patients with COVID-19. Individuals with any blood type should continue to take the same precautions like wearing a mask, social distancing, and washing hands effectively.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More